Istituto Clinico Humanitas
immune evaluation(Istituto Clinico Humanitas)은 Oligorecurrent and Oligoprogressive Pros 표적 세포·유전자 치료로, Oligorecurrent and Oligoprogressive Prostate Cancer Patients 영역에서 개발·상용화 중입니다. 작용기전: of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying pati. 전임상 단계입니다. 대표 임상 효능: ORR 37.5% (ClinicalTrials.gov NCT05228470). 차별점: novel form of KAR‑mediated LTD in the ACC that depends on GluK1‑containing KARs and the Ca²⁺‑.
Oligorecurrent and Oligoprogressive Pros
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Recruiting
oncolytic HSV1 and radiotherapy via triple combination therapy
retroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs)
novel form of KAR‑mediated LTD in the ACC that depends on GluK1‑containing KARs and the Ca²⁺‑
of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic
cytokine release syndrome occurred
apoptosis
biomarkers
resistance to cisplatin (p = 0
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Istituto Clinico Humanitas
immune evaluation(Istituto Clinico Humanitas)은 Oligorecurrent and Oligoprogressive Pros 표적 세포·유전자 치료로, Oligorecurrent and Oligoprogressive Prostate Cancer Patients 영역에서 개발·상용화 중입니다. 작용기전: of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying pati. 전임상 단계입니다. 대표 임상 효능: ORR 37.5% (ClinicalTrials.gov NCT05228470). 차별점: novel form of KAR‑mediated LTD in the ACC that depends on GluK1‑containing KARs and the Ca²⁺‑.
Oligorecurrent and Oligoprogressive Pros
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
Recruiting
oncolytic HSV1 and radiotherapy via triple combination therapy
retroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs)
novel form of KAR‑mediated LTD in the ACC that depends on GluK1‑containing KARs and the Ca²⁺‑
of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic
cytokine release syndrome occurred
apoptosis
biomarkers
resistance to cisplatin (p = 0
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.